Investigational drug · Phase 3
SHR-1905
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Asthma, Chronic Rhinosinusitis With Nasal Polyps, Moderate-to-severe Atopic Dermatitis.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
3 still active
All registered trials
9
Any phase or sponsor naming "SHR-1905"
First trial start
2023
Jan 17, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SHR-1905", any sponsor or status.
Conditions studied
As listed on its trial records.
- Asthma
- Chronic Rhinosinusitis With Nasal Polyps
- Moderate-to-severe Atopic Dermatitis
- Adolescent Asthma
Approved drugs for the same conditions: Atopic dermatitis (eczema) · Asthma · Immunology and inflammation · Respiratory · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "SHR-1905" as an intervention, largest first.
- A Trial of SHR-1905 in Subjects With Severe Uncontrolled AsthmaPivotal-lookingRecruiting
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT07098403 · 408 participants (planned) · Start Sep 3, 2025 · Primary completion Jan 2028
Drug: SHR-1905 Injection; SHR-1905 Placebo Injection · For: Asthma
Sites: Guangzhou, China
- A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled AsthmaPivotal-lookingActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT06748053 · 307 participants · Start Feb 10, 2025 · Primary completion Jul 14, 2026
Drug: GSK5784283; Placebo · For: Asthma
Sites: Little Rock, Arkansas; Long Beach, California; Los Angeles, California · 137 sites in all
- Efficacy and Safety of SHR-1905 Injection in Subjects With Chronic Rhinosinusitis With Nasal PolypsPivotal-lookingRecruiting
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT07132827 · 280 participants (planned) · Start Aug 28, 2025 · Primary completion Apr 2028
Drug: SHR-1905 Injection; SHR-1905 Placebo Injection · For: Chronic Rhinosinusitis With Nasal Polyps
Sites: Shanghai, China
- A Trial of SHR-1905 in Subjects With Severe Uncontrolled AsthmaPivotal-lookingCompleted
Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
NCT05593250 · 260 participants · Start Jan 17, 2023 · Primary completion Dec 5, 2025
Drug: SHR-1905; placebo · For: Asthma
Sites: Guangzhou, China
- Efficacy and Safety of SHR-1905 Injection in Patients With Chronic Rhinosinusitis With Nasal PolypsPivotal-lookingCompleted
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT05891483 · 114 participants · Start Sep 4, 2023 · Primary completion Jan 21, 2026
Drug: SHR-1905 Injection; SHR-1905 Placebo Injection · For: Chronic Rhinosinusitis With Nasal Polyps
Sites: Shanghai, China
Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
NCT04905602 · 86 participants · Start Jun 15, 2021 · Primary completion Oct 9, 2023
Drug: SHR-1905/placebo · For: Asthma
Sites: Shanghai, China
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT07211542 · 75 participants (planned) · Start Nov 7, 2025 · Primary completion Sep 2026
Drug: SHR-1905 Injection; SHR-1905 Injection Blank Preparation · For: Moderate-to-severe Atopic Dermatitis
Sites: Guangzhou, China
Atridia Pty Ltd.Industry
NCT04800263 · 50 participants · Start Jul 27, 2021 · Primary completion Nov 12, 2022
Drug: SHR-1905; Placebo · For: Asthma
Sites: Brisbane, Australia
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT06786455 · 9 participants · Start Jan 23, 2025 · Primary completion Dec 3, 2025
Drug: SHR-1905 Injection · For: Adolescent Asthma
Sites: Guangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- Lessons learned from clinical trials of thymic stromal lymphopoietin inhibition.
Corren J, Borish L, Brightling C, et al. · J Allergy Clin Immunol 2026
- A phase 1, randomized, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of SHR-1905, a long-acting anti-thymic stromal lymphopoietin antibody, in healthy subjects.
Fei Y, Li N, Qian W, et al. · Front Pharmacol 2024
Also in development for Asthma
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- LunsekimigSAR443765Phase 39 trials
Sanofi · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps
- GSK5784283Phase 38 trials
GSK · Pulmonary Disease, Chronic Obstructive, Asthma, Nasal Polyps
- PF-07275315tilrekimigPhase 38 trials
Pfizer · Atopic Dermatitis, Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- TozorakimabMEDI3506Phase 36 trials
AstraZeneca · Chronic Obstructive Pulmonary Disease (COPD), Asthma, Viral Lung Infection and Acute Respiratory Failure
- TQC2731Phase 35 trials
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
- BFFBFF MDI 320, BFF MDI 160Phase 34 trials
AstraZeneca · Asthma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.